Johnson & Johnson's DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Portfolio Pulse from
Johnson & Johnson's DARZALEX® (daratumumab) subcutaneous-based regimen has received a positive opinion from the CHMP for treating newly diagnosed multiple myeloma patients, regardless of transplant eligibility. If approved, it will be the only anti-CD38 therapy available for all patient types, solidifying its role as a foundational therapy.
February 28, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's DARZALEX® receives positive CHMP opinion for treating newly diagnosed multiple myeloma, potentially becoming the only anti-CD38 therapy for all patient types.
The positive CHMP opinion for DARZALEX® indicates a strong likelihood of approval, which would make it the only anti-CD38 therapy available for all newly diagnosed multiple myeloma patients. This positions DARZALEX® as a foundational therapy, potentially increasing its market share and revenue for JNJ.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90